EPCAM and breast carcinoma: Data pooled from both EpCAM+ and EpCAM- breast cancer mouse models showed that the number of CTCs captured by the microfluidic CTC capture chip ranged from 13 to 4,664 cells per 100 μL of blood and increased drastically over the 9-week period during tumor progression, correlating positively with an increase in tumor weight (Fig. 3c-e).